Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, October 13, 2016
Aptuit has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to meet sustained customer demand for IND de-risking and enabling packages.
read more
Wednesday, November 30, 2016
Aptuit announced that it has successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to over 400,000.
read more
Friday, February 22, 2013
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the company has formed the Aptuit Scientific Advisory Board (SAB) comprised of scientific experts from within the company. The SAB will regularly meet to assess ...
read more
Monday, November 12, 2012
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the number of clients placing work at The Aptuit Center for Drug Discovery & Development in Verona, Italy has reached 100, giving the site a strong vote of confidence...
read more
Aptuit LLC announced that the company has innovated a translational strategy that represents a unique approach, known as “Complementary Vision,” for those in search of high value Chemistry, Manufacturing and Control (CMC) services.
read more
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced that the company has launched an interactive link, “Ask an Expert,” on its website to provide informational support to the pharmaceutical community.
read more
Greenwich, CT, March 15, 2012 - Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, Stuart E. Needleman has been named President and Chief Operating Officer of Aptuit LLC. Following the recent sale of the company’s Clinical ...
read more
Aptuit LLC announces the appointment of two new members to its Executive Leadership team. Kurt Dinkelacker has been named Executive Vice President and Chief Financial Officer and Kevin Duffield has been promoted to Vice President, Sales and Business ...
read more
Aptuit has announced that Dr. Maurizio Denaro has assumed responsibilities as General Manager of The Aptuit Center for Discovery & Development in Verona, Italy, effective July 15, 2013.
read more
Aptuit LLC has appointed Paul D. Overton, Ph.D., as Executive Vice President, Business Development and Marketing, making him responsible for all of Aptuit's sales and marketing activities.
read more
Wednesday, December 04, 2013
Timothy C. Tyson, Chairman of Aptuit LLC, announced today the appointment of Jonathan Goldman, MD as Chief Executive Officer (CEO), completing the company’s senior management leadership team.
read more
Monday, November 28, 2016
Aptuit announced that Peter Gray has been appointed Chairman of Aptuit's Board of Managers.
Mr. Gray assumes the role of Chairman having previously served as Non-Executive Director since March 2015.
read more
Monday, February 11, 2013
Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, announced the availability of GLP-qPCR Biodistribution Studies required as part of the preclinical development study package for application in First In Man (FIM) of Gene Therapy ...
read more
Wednesday, March 27, 2013
Aptuit announces that it offers fast screenings of synaptic activity on hippocampal slices for clients who are focused on the central nervous system (CNS) therapeutic area.
read more
Thursday, January 31, 2019
Aquestive Therapeutics has learned its licensee, Sunovion Pharmaceuticals, received a CRL from the FDA in response to the NDA for apomorphine sublingual film (APL-130277).
read more